Advanced Therapy Medicinal Products and the Changing Role of Academia.
Transfus Med Hemother
2022
49
3
158-162
Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.
J Clin Oncol
2022
40 Suppl S
16
[Importance of clonal hematopoiesis for hematologic neoplasms].
Inn Med (Heidelb)
2022
63
11
1107-1114
SPPL3 and its substrate glycosyltransferases regulate the N-glycosylation of SLC3A2 and alter the affinities of anti-SLC3A2 immunotherapies in AML
Oncology Research and Treatment
2022
45 Suppl 2
SUPPL 2
95-95
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Blood
2022
140 Suppl 1
3338-3340
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
Blood
2022
140 Suppl 1
1109-1111
Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines.
Front Oncol
2022
12
Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression
Blood
2022
140 Suppl 1
9840-9841
Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
Blood
2022
140 Suppl 1
2010-2013
Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
Blood
2022
140 Suppl 1
1128-1129